U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06963814) titled 'Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors' on April 30.
Brief Summary: This is an open-label, multicenter Phase 1b clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of HC006 in combination with a PD-1 inhibitor in patients with advanced solid tumors. The trial is divided into two stages: dose-escalation and dose expansion. First, the dose-escalation study is completed to determine the recommended dose for subsequent extension studies, and then the dose expansion study is conducted in the proposed tumors with potential treatme...